Safety evaluation of combined PD-1+CTLA4 inhibition concurrently to chemoradiotherapy (CRT) in localized muscle invasive bladder carcinoma (MIBC).

Ben-Max de Ruiter,Jons Wouter van Hattum,Theo M. de Reijke,Jorg R. Oddens,Maarten C. C. M. Hulshof,Adriaan D. Bins

Safety evaluation of combined PD-1+CTLA4 inhibition concurrently to chemoradiotherapy (CRT) in localized muscle invasive bladder carcinoma (MIBC).

2021

Ben-Max de Ruiter
Jons Wouter van Hattum
Theo M. de Reijke
Jorg R. Oddens
Maarten C. C. M. Hulshof
Adriaan D. Bins

4531Background: Neoadjuvant nivolumab (nivo) + ipilimumab (ipi) prior to radical cystectomy showed efficacy in localized MIBC. The safety of PD-1 and PDL-1+CTLA4 inhibition concurrent with CRT in l...

Keywords:

Cystectomy
Nivolumab
Carcinoma
Medicine
Chemoradiotherapy
Ipilimumab
muscle invasive
Urology

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations